ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO995

Effect of Omega-3 Fatty Acid on AKT-mTOR and FoxO in Heart of 5/6 Nephrectomy Rat Model

Session Information

Category: Hypertension and CVD

  • 1403 Hypertension and CVD: Mechanisms

Authors

  • Lee, Su mi, Dong-A University, Busan, Korea (the Republic of)
  • Oh, Yun Jung, Cheju Halla General Hospital, Jeju, Korea (the Republic of)
  • Son, Young ki, Dong-A University, Busan, Korea (the Republic of)
  • Kim, Seong Eun, Dong-A University Hospital, Busan, Korea (the Republic of)
  • An, Won Suk, Dong-A University, Busan, Korea (the Republic of)
Background

Cardiac hypertrophy is common and results in mortality in patients with chronic kidney disease (CKD). Akt-mammalian target of rapamycin (mTOR) axis is related with cardiac hypertrophy. Forkhead box class O (FoxO) family is related with autophagy and apoptosis, but there is no report in the heart of CKD. The present study aimed to investigate whether omega-3 fatty acid (ω-3 FA) effect on Akt-mTOR axis and FoxO in heart of 5/6 subtotal nephrectomy (Nx) rat model.

Methods

Male Sprague Dawley rats were divided into three groups and treated for 6 weeks: sham control (0.9% saline), 5/6 Nx control (0.9% saline) and 5/6 Nx treated with ω-3 FA (300 mg/kg/day by gastric gavage). The expression of cardiac Akt, phosphorylated(p) Akt, mTOR, FoxO, PI3K, p-PI3k, AMPK, p-AMPK, smad2/3, NF-κB, cleaved caspase 3/7, LC3, muscle-specific ring finger protein-1 (MuRF1), and muscle atrophy F-box protein (MAFbx) were examined by western blot analysis. Hematoxylin and eosin staining of heart was performed.

Results

Serum creatinine level was significantly increased in 5/6 Nx group compared to control group and were not significantly different between 5/6 Nx group treated with ω-3 FA and 5/6 Nx group. Compared with control group, cardiac hypertrophy of 5/6 Nx group was found in gross and microscopic findings. No definite cardiac hypertrophy was found in 5/6 Nx group treated with ω-3 FA. P-Akt and mTOR were significantly up-regulated in heart of 5/6 Nx group compared to control group and were recovered by ω-3 FA. Compared with control group, 5/6 Nx group significantly up-regulated FoxO1 and FoxO3a expression of heart, which were significantly recovered by ω-3 FA. However, the expression of MuRF1 and MAFbx was not different among three groups. The expression of smad2/3, NF-κB, cleaved caspase 3/7, LC3 was up-regulated in the heart of 5/6 Nx group compared to control group and was recovered by ω-3 FA. The expression of p-AMPK was down-regulated in the heart of 5/6 Nx group compared to control group and was recovered by ω-3 FA.

Conclusion

ω-3 FA may prevent cardiac hypertrophy not only by decreasing p-Akt, mTOR and FoxO expression but also by reducing molecules of inflammation, autophagy and apoptosis.